Company

Tyrogenex

As of the edition of 20 October 2026, Tyrogenex runs 1 drug; it is on route A at 5 targets and on route B at 0 targets.

Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.

Drugs by status

Status	Count
Stopped	1
Total	1

Status

Count

Stopped

Total

Route A at 5 targets, route B at 0 targets.

Three of its 5 rows, by target and route
Target	Route
KDR Vascular endothelial growth factor receptor 2	Route A
FLT4 Vascular endothelial growth factor receptor 3	Route A
FLT1 Vascular endothelial growth factor receptor 1	Route A

In the product

5 company-target rows on route A or B; 2 are not shown here, and no score is.